Current Treatment Options in Cardiovascular Medicine

, Volume 8, Issue 5, pp 396–402

Cardiovascular management of marfan syndrome in the young

  • Angela M. Sharkey
Article

Opinion statement

Marfan syndrome is an autosomal-dominant disorder of connective tissue resulting from a mutation in the fibrillin gene. Manifestations of the disorder primarily affect the skeletal, cardiovascular, and ocular systems. The phenotypic manifestations of this disorder can be quite variable. The major cause of morbidity and mortality in this patient population is the cardiovascular manifestations of the disorder: aortic root dilation and dissection. Individuals with this disorder are at risk for catastrophic cardiovascular events, most often as a result of aortic dissection. Although the incidence of dissection in childhood is exceedingly low, the background of a progressively dilating aortic root appears to be the major factor contributing to this risk in adulthood. Therefore, it is beneficial to identify affected individuals as early as possible to institute lifestyle changes and medical therapy in an effort to enhance their long-term outcome. Familial screening, once a case has been identified, and consideration of genetic screening of an affected family may also be helpful. Medical therapy with β blockers, calcium channel blockers, and/or angiotensin inhibitors has been shown to be somewhat effective in slowing the rate of growth of the aorta. Exciting new data suggest that angiotensin II receptor antagonists may provide an even greater degree of protection from aortic dilatation in this population. Despite medical therapy, patients with Marfan syndrome do have progressive dilatation of their aortic root. The risk of aortic dissection increases with increasing size of the aorta. Prophylactic surgical techniques have been successful in reducing the morbidity and mortality associated with aortic dissection, resulting in a longer average life span in this patient population.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pyeritz RE: Marfan syndrome and other disorders of fibrillin. In Principles and Practice of Medical Genetics, edn 3. Edited by Rimoin DL, et al. New York: Churchill Livingstone; 1997:1027–1066.Google Scholar
  2. 2.
    Dietz HC, Cutting GR, Pyeritz RE, et al: Defects in the fibrillin gene cause the Marfan syndrome: linkage evidence and identification of a missense mutation. Nature 1991, 352:337–339.PubMedCrossRefGoogle Scholar
  3. 3.
    Collod-Beroud G: Marfan database. Nucleic Acids Res 1998, 26:229–233.PubMedCrossRefGoogle Scholar
  4. 4.
    Murdoch JL, Walker BA, Halpern BL, et al: Life expectancy and causes of death in the Marfan Syndrome. N Engl J Med 1972, 286:804–808.PubMedCrossRefGoogle Scholar
  5. 5.
    Shores J, Berger KR, Murphy EA, et al: Progression of aortic dilatation and the benefit of long-term betaadrenergic blockade in Marfan’s syndrome. N Engl J Med 1994, 330:1335–1341.PubMedCrossRefGoogle Scholar
  6. 6.
    Pyreitz RE: Effectiveness of beta-adrenergic blockade in the Marfan syndrome: experience over 10 years. Am J Med Genet 1989, 32:245.Google Scholar
  7. 7.
    Gray JR, Bridges AB, West RR, et al: Life expectancy in British Marfan syndrome populations. Clin Genet 1998, 54:124–128.PubMedCrossRefGoogle Scholar
  8. 8.
    Silverman DI, Burton KJ, Gray J, et al: Life expectancy in the Marfan syndrome. Am J Cardiol 1995, 75:157–160.PubMedCrossRefGoogle Scholar
  9. 9.
    DePaepe A, Deitz HC, Devereux RB, et al: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62:417–426.CrossRefGoogle Scholar
  10. 10.
    Health supervision for children with Marfan syndrome. American Academy of Pediatrics Committee on Genetics [no authors listed]. Pediatrics 1996, 98:978–982.Google Scholar
  11. 11.
    National Marfan Foundation. Available at http://www.marfan.org/nmf/. Accessed April 2006.Google Scholar
  12. 12.
    Dean JCS: Management of Marfan syndrome. Heart 2002, 88:97–103.PubMedCrossRefGoogle Scholar
  13. 13.
    Roman MJ, Devereux RB, Kramer-Fox R, et al: Twodimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989, 64:507–512.PubMedCrossRefGoogle Scholar
  14. 14.
    Loeys BL, Chen J, Neptune ER, et al: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275–281.PubMedCrossRefGoogle Scholar
  15. 15.
    Pyeritz RE: The Marfan syndrome. Ann Rev Med 2000, 51:481–510.PubMedCrossRefGoogle Scholar
  16. 16.
    Dietz HC, Pyeritz RE: Marfan syndrome and related disorders. In The Metabolic and Molecular Bases of Inherited Disease, edn 8. Edited by Scriver CR, et al. New York: McGraw-Hill; 2000:5287–5311.Google Scholar
  17. 17.
    Maron BJ, Chaitman BR, Ackerman MJ, et al: Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807–2816.PubMedCrossRefGoogle Scholar
  18. 18.
    Maron BJ: Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005, 45:1340–1345.PubMedCrossRefGoogle Scholar
  19. 19.
    Milewicz DM, Dietz HC, Miller DC: Treatment of aortic disease in patients with Marfan Syndrome. Circulation 2005, 111:e150-e157. A concise, thorough review of the Marfan syndrome. The focus is predominantly on the cardiovascular manifestations of Marfan syndrome and their medical and surgical management.PubMedCrossRefGoogle Scholar
  20. 20.
    Rossi-Foulkes R, Roman MJ, Rosen SE, et al: Phenotypic features and impact of beta blocker or calcium channel antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999, 83:1364–1368.PubMedCrossRefGoogle Scholar
  21. 21.
    Yetman AT, Bornemeier RA, McCrindle BW: Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005, 95:1125–1127.PubMedCrossRefGoogle Scholar
  22. 22.
    Dietz HC, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet Part C Semin Med Genet 2005, 139:4–9.Google Scholar
  23. 23.
    Judge DP, Dietz HC: Marfan’s syndrome. Lancet 2005, 366:1965–1976. An excellent review of the Marfan syndrome. Additional data include a listing of other syndromes that present with similar phenotypic characteristics to the Marfan syndrome. Also, a discussion of the most current genetic studies leading to potential advances in medical therapeutics is presented.PubMedCrossRefGoogle Scholar
  24. 24.
    Kim SY, Martin N, Hsia EC, et al: Management of aortic disease in Marfan syndrome: a decision analysis. Arch Intern Med 2005, 165:749–755.PubMedCrossRefGoogle Scholar
  25. 25.
    Davies RR, Goldstein LJ, Coady MA, et al: Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002, 73:17–27; discussion 27–28.PubMedCrossRefGoogle Scholar
  26. 26.
    Zehr KJ, Matloobi A, Connolly HM, et al: Surgical management of the aortic root in patients with Marfan syndrome. J Heart Valve Dis 2005, 14:121–128;discussion 128–129.PubMedGoogle Scholar
  27. 27.
    Vricella LA, Williams JA, Ravekes WJ, et al: Early experience with valve-sparing aortic root replacement in children. Ann Thorac Surg 2005, 80:1622–1626; discussion 1626–1627.PubMedCrossRefGoogle Scholar
  28. 28.
    Pyeritz RE: The Marfan syndrome in childhood: features, natural history and differential diagnosis. Prog Pediatr Cardiol 1996, 5:151–157.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Angela M. Sharkey
    • 1
  1. 1.Division of Pediatric CardiologyWashington University School of Medicine, One Children’s PlaceSt. LouisUSA

Personalised recommendations